Sarfaraz 2018.

Study characteristics
Patient Sampling	Cohort, manner of selection not reported, prospective
Patient characteristics and setting	Presenting signs and symptoms: patients presenting with 1 or more superficial lymph nodes (i.e. cervical, axillary, and inguinal nodes) measuring > 2 cm in largest diameter and persisting for more than 1 month, with or without constitutional symptoms of fever, anorexia, and weight loss Age: > 14 years of age; median 23 years (IQR 18 to 32) Sex, female: 79% Children: no HIV infection: 1% Clinical setting: outpatient Past history of TB: not reported Participants on anti‐TB treatment: not reported Number of specimens evaluated: 261 Laboratory level: central Country: Pakistan World Bank Income Classification: middle income High TB burden: yes High TB/HIV burden: no High MDR‐TB burden: yes
Index tests	Xpert MTB/RIF WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s)	Lymph node TB, tissue MGIT; LJ Composite reference standard includes histopathology Rifampicin resistance MGIT‐DST Speciation: not reported Decontamination: yes (NALC–NaOH)
Flow and timing
Comparative
Notes
Methodological quality
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled?	Unclear
Was a case‐control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
Could the selection of patients have introduced bias?		Unclear risk
Are there concerns that the included patients and setting do not match the review question?			Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
If a threshold was used, was it pre‐specified?	Yes
Could the conduct or interpretation of the index test have introduced bias?		Low risk
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition?	Unclear
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test?	Yes
Could the reference standard, its conduct, or its interpretation have introduced bias?		Unclear risk
Are there concerns that the target condition as defined by the reference standard does not match the question?			Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes
Could the patient flow have introduced bias?		Low risk